Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia

DOI: 10.1158/2159-8290.CD-RW2019-188 Published February 2020
  • Article
  • Info & Metrics
Loading
  • Major Finding: Asciminib was tolerable and had preliminary evidence of efficacy in chronic myeloid leukemia (CML).

  • Concept: In a phase I trial, patients were treated with asciminib, an allosteric tyrosine kinase inhibitor (TKI).

  • Impact: With its tolerability and unique mechanism, asciminib may be a TKI of choice for some patients with CML.

Treatment with tyrosine kinase inhibitors (TKI) can produce durable responses in patients with chronic myeloid leukemia (CML), but resistance or unacceptable side effects limit the use of TKIs in some patients. In a phase I clinical trial, Hughes, Mauro, and colleagues investigated the use of asciminib in 141 patients with chronic-phase and 9 patients with accelerated-phase CML, all 150 of whom were positive for the Philadelphia chromosome. Asciminib is unique among currently available TKIs in that it does not interact with the ATP-binding site of the ABL1 kinase but rather allosterically inhibits the enzyme; thus, disease resistant to other TKIs may respond to asciminib treatment. All enrolled patients had been treated with at least two prior TKIs or had been treated with one prior TKI but had no other effective options. All patients experienced at least one side effect, with the most common being rash, constitutional symptoms (e.g., fatigue, headache, nausea), and increased lipase or amylase levels. Of the 110 evaluable patients without the T315I “gatekeeper” mutation in BCR–ABL1, complete cytogenetic response was attained in 77 (70%) patients. Of the 25 evaluable patients with the T315I mutation, 11 (44%) patients experienced a complete cytogenetic response. This response rate is notable because the only clinically available agent with much efficacy in patients with the T315I mutation is ponatinib, but ponatinib's side-effect profile makes it unsuitable for some patients. In line with predictions from preclinical in vitro studies, higher doses of asciminib were required in the group with the T315I mutation. However, contrasting with predictions from earlier in vitro studies, the preliminary evidence from this trial does not support the notion that asciminib treatment frequently results in mutations in ABL1′s myristoyl-binding pocket, asciminib's binding site. In summary, this trial demonstrates that asciminib is tolerable and exhibits preliminary evidence of efficacy in patients with CML who have not attained responses from treatment with other TKIs.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381:2315–26.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia
Cancer Discov February 1 2020 (10) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2019-188

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia
Cancer Discov February 1 2020 (10) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2019-188
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Clinical Trials

  • Hematopoietic Stem Cell Renewal Drives Myeloproliferative Neoplasms
  • Epithelioid Sarcoma Responds to the Oral EZH2 Inhibitor Tazemetostat
  • The LSD1 Inhibitor Iadademstat Is Active in Acute Myeloid Leukemia
Show more Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement